Kazia Therapeutics Ltd

KZIA chart

Kazia Therapeutics Ltd news

• Certain Options of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 28-OCT-2026.

  www.marketscreener.com · Oct 27, 9:12 PM EDT

• Kazia Therapeutics Limited Stock 12‑Month Price Target Raised to $31.83, Implies 308% Upside

  TradingView · Oct 24, 6:20 PM EDT

• Kazia Therapeutics Limited Stock Price Today | KZIA Live Chart & News

  Traders Union · Oct 23, 3:00 AM EDT

• Guggenheim initiates Kazia Therapeutics stock with buy rating

  Investing.com · Oct 21, 9:19 AM EDT

• Guggenheim initiates coverage of Kazia Therapeutics with Buy rating, $35 price target

  TradingView · Oct 21, 9:08 AM EDT

• Guggenheim Initiates Kazia Therapeutics at Buy With $35 Price Target

  Moomoo · Oct 21, 7:28 AM EDT

• Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

  Yahoo Finance · Sep 22, 7:30 AM EDT

• Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate

  Yahoo Finance · Sep 19, 6:15 PM EDT

• Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

  Yahoo Finance · Sep 9, 7:30 AM EDT

• Kazia (KZIA) Raises Approximately $40M in Gross Proceeds and Expands Paxalisib. Is the Capital Base Stronger than the Clinical Evidence?

  Yahoo Finance · Sep 9, 12:05 AM EDT

• Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study

  Yahoo Finance · Sep 1, 8:30 AM EDT

• Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy

  Yahoo Finance · Sep 1, 7:30 AM EDT

Kazia Therapeutics Ltd key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-22
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-18
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-01
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-31
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-31
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-28
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-27
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-28
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-02
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-05-26
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-04-27
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-04-15

About Kazia Therapeutics Ltd

Ticker

KZIA (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Sydney Nsw

Incorporated in

Australia

Fiscal year end

June 30

SEC CIK

1075880

Former names

NOVOGEN LTD

Frequently asked questions